Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

No phase specified

Diagnostic

Active

18 and over

Other

05-023
NCT00588276

Trial Description

Summary

The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment. A tracer is an extremely small quantity of a substance. Tracer to which radioactivity has been attached may be used to "trace" events in the body. A tracer called iodo-azomycin galactopyranoside (or *IAZGP) appears to be able to detect low oxygen areas within tumor.

Radioactive iodine in this molecule can be detected by an imaging technique called a PET scan. This present study involves obtaining three scans using this new imaging technique. The goal of carrying out many scans is to determine which scan will best show any areas in your tumor that may have low levels of oxygen.

Eligibility Criteria

Inclusion Criteria:

Patients must have locally advanced cancer as determined by currently accepted diagnostic work-up, including CT/MR/US.

KPS >70%.

Patients must be > or equal to 18 years of age.

Exclusion Criteria:

Patients will be excluded from the study if they fulfill any of the following criteria:

Patients with abnormal baseline thyroid function tests, or any thyroid disorder including but not limited to hypothyroidism and thyroiditis. Patients with thyroid cancer who have had a thyroidectomy are not excluded.

Patients who are pregnant or lactating.

Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.

Patients who cannot tolerate being in the PET scanner for the duration of the study.

Trial Contact Information

Trial Lead Organizations/Sponsors

Memorial Sloan-Kettering Cancer Center

Heiko Schöder, MD

Principal Investigator

Heiko Schöder, MD
		Email: schoderh@mskcc.org

Nancy Lee, MD		Ph: 212-639-3341
		Email: leen2@mskcc.org

Trial Sites

U.S.A.

New York

New York

Memorial Sloan-Kettering Cancer Center

Heiko Schöder, MD

Email: schoderh@mskcc.org

Nancy Lee, MD Ph: 212-639-3341

Email: leen2@mskcc.org

Heiko Schoder, MD Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00588276
Information obtained from ClinicalTrials.gov on September 11, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.